Rakovina Therapeutics expands Variational AI pact, gains exclusivity on kt — 5000 ATR inhibitor target profile
Rakovina Therapeutics amended, extended its research services deal with Variational AI for the kt-5000 ATR inhibitor program. Amendment grants exclusivity on a defined target product profile covering potency, selectivity, drug-like properties, brain penetration for the agreed term. Variational AI to run additional Enki